380 related articles for article (PubMed ID: 24135284)
1. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis.
Ell B; Mercatali L; Ibrahim T; Campbell N; Schwarzenbach H; Pantel K; Amadori D; Kang Y
Cancer Cell; 2013 Oct; 24(4):542-56. PubMed ID: 24135284
[TBL] [Abstract][Full Text] [Related]
2. Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis.
Kitayama K; Kawamoto T; Kawakami Y; Hara H; Takemori T; Fujiwara S; Yahiro S; Miyamoto T; Mifune Y; Hoshino Y; Kakutani K; Matsumoto T; Matsushita T; Niikura T; Kuroda R; Akisue T
Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34713296
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror.
Waning DL; Mohammad KS; Guise TA
Cancer Cell; 2013 Oct; 24(4):407-9. PubMed ID: 24135278
[TBL] [Abstract][Full Text] [Related]
4. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
Liu J; Li D; Dang L; Liang C; Guo B; Lu C; He X; Cheung HY; He B; Liu B; Li F; Lu J; Wang L; Shaikh AB; Jiang F; Lu C; Peng S; Zhang Z; Zhang BT; Pan X; Xiao L; Lu A; Zhang G
Sci Rep; 2017 Jan; 7():40487. PubMed ID: 28071724
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein.
Kuo PL; Liao SH; Hung JY; Huang MS; Hsu YL
Biochim Biophys Acta; 2013 Jun; 1830(6):3756-66. PubMed ID: 23458685
[TBL] [Abstract][Full Text] [Related]
8. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
Li X; Liang Y; Lian C; Peng F; Xiao Y; He Y; Ma C; Wang Y; Zhang P; Deng Y; Su Y; Luo C; Kong X; Yang Q; Liu T; Hu G
Theranostics; 2021; 11(20):9821-9832. PubMed ID: 34815788
[No Abstract] [Full Text] [Related]
9. Small extracellular vesicles deliver osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic niche.
Ma Q; Liang M; Wu Y; Dou C; Xu J; Dong S; Luo F
J Extracell Vesicles; 2021 Feb; 10(4):e12068. PubMed ID: 33659051
[TBL] [Abstract][Full Text] [Related]
10. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
[TBL] [Abstract][Full Text] [Related]
11. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p.
Yu L; Sui B; Fan W; Lei L; Zhou L; Yang L; Diao Y; Zhang Y; Li Z; Liu J; Hao X
J Extracell Vesicles; 2021 Jan; 10(3):e12056. PubMed ID: 33489015
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
Marino S; Bishop RT; Mollat P; Idris AI
Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
[TBL] [Abstract][Full Text] [Related]
13. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
Sung B; Oyajobi B; Aggarwal BB
Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells.
Yuan X; Qian N; Ling S; Li Y; Sun W; Li J; Du R; Zhong G; Liu C; Yu G; Cao D; Liu Z; Wang Y; Qi Z; Yao Y; Wang F; Liu J; Hao S; Jin X; Zhao Y; Xue J; Zhao D; Gao X; Liang S; Li Y; Song J; Yu S; Li Y
Theranostics; 2021; 11(3):1429-1445. PubMed ID: 33391543
[No Abstract] [Full Text] [Related]
15. Osteoclast signaling-targeting miR-146a-3p and miR-155-5p are downregulated in Paget's disease of bone.
Stephens E; Roy M; Bisson M; Nguyen HD; Scott MS; Boire G; Bouchard L; Roux S
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165852. PubMed ID: 32485219
[TBL] [Abstract][Full Text] [Related]
16. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-κB and ERK.
Ang ES; Pavlos NJ; Chim SM; Feng HT; Scaife RM; Steer JH; Zheng MH; Xu J
J Cell Biochem; 2012 Mar; 113(3):946-55. PubMed ID: 22034016
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo.
Marino S; Bishop RT; Carrasco G; Logan JG; Li B; Idris AI
Calcif Tissue Int; 2019 Aug; 105(2):193-204. PubMed ID: 30929064
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts.
Grano M; Mori G; Minielli V; Cantatore FP; Colucci S; Zallone AZ
Biochem Biophys Res Commun; 2000 Apr; 270(3):1097-100. PubMed ID: 10772956
[TBL] [Abstract][Full Text] [Related]
20. Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo.
Frantzias J; Logan JG; Mollat P; Sparatore A; Del Soldato P; Ralston SH; Idris AI
Br J Pharmacol; 2012 Mar; 165(6):1914-1925. PubMed ID: 21955294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]